In an attempt to understand how SPHK inhibitors reduce the generation of venetoclax resistance in our in vitro system, we evaluated the expression of BCL-XL and MCL-1 in CLL cells, which are not targeted by venetoclax. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.